Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

$24.99

Enterprise Value to FCFF (EV/FCFF)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Free Cash Flow to The Firm (FCFF)

Vertex Pharmaceuticals Inc., FCFF calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net income (loss)
Net noncash charges
Changes in operating assets and liabilities
Net cash provided by (used in) operating activities
Cash paid for interest, net of tax1
Purchases of property and equipment
Free cash flow to the firm (FCFF)

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The financial information reveals fluctuating performance in net cash provided by operating activities and free cash flow to the firm (FCFF) over the five-year period. A general pattern of volatility is apparent, with significant shifts occurring between consecutive years.

Operating Cash Flow
Net cash provided by operating activities demonstrated substantial growth from 2021 to 2022, increasing from US$2.64 billion to US$4.13 billion. This positive trend reversed in 2023, with a decrease to US$3.54 billion. A dramatic shift occurred in 2024, resulting in a net cash *use* of US$0.49 billion. A recovery was then observed in 2025, with operating cash flow returning to US$3.63 billion.
Free Cash Flow to the Firm (FCFF)
FCFF mirrored the trend observed in operating cash flow. It increased significantly from US$2.46 billion in 2021 to US$3.97 billion in 2022. A decline followed in 2023, reaching US$3.37 billion. The most substantial change occurred in 2024, with FCFF becoming negative at -US$0.77 billion. FCFF recovered in 2025, reaching US$3.20 billion, though remaining below the 2022 peak.

The correlation between operating cash flow and FCFF is strong, suggesting that changes in operating activities are the primary driver of fluctuations in free cash flow. The negative FCFF in 2024 warrants further investigation to understand the underlying causes, such as potential increases in capital expenditures or changes in working capital requirements. The recovery in 2025 indicates a potential stabilization, but continued monitoring is recommended to assess the sustainability of this improvement.

Overall Trend
While there is an overall positive level of FCFF across most of the period, the significant volatility observed suggests potential instability or sensitivity to external factors. The company experienced a period of strong cash generation followed by a substantial downturn, and then a partial recovery. This pattern highlights the importance of understanding the drivers behind these fluctuations.

Interest Paid, Net of Tax

Vertex Pharmaceuticals Inc., interest paid, net of tax calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Effective Income Tax Rate (EITR)
EITR1
Interest Paid, Net of Tax
Cash paid for interest, before tax
Less: Cash paid for interest, tax2
Cash paid for interest, net of tax

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 See details »

2 2025 Calculation
Cash paid for interest, tax = Cash paid for interest × EITR
= × =


A consistent decline in cash paid for interest, net of tax, is observed over the five-year period. This decrease occurs alongside fluctuations in the effective income tax rate.

Cash Paid for Interest, Net of Tax
The amount of cash paid for interest, net of tax, decreased significantly from US$48.305 million in 2021 to US$10.552 million in 2025. A year-over-year reduction is present in each year of the period. The largest decrease occurred between 2023 and 2024, with a reduction of US$11.506 million. The rate of decline appears to be accelerating in the later years.
Effective Income Tax Rate
The effective income tax rate exhibited volatility throughout the period. It increased from 14.20% in 2021 to 21.50% in 2022, then decreased to 17.40% in 2023, rose again to 21.00% in 2024, and finally decreased to 14.90% in 2025. The fluctuations suggest changes in the composition of taxable income or the utilization of tax credits or deductions.
Relationship between Interest Paid and Tax Rate
While a clear correlation is not immediately apparent, the decreasing trend in net interest paid occurs concurrently with changes in the effective income tax rate. The tax rate increases in 2022 and 2024 do not appear to halt the decline in net interest expense. Further investigation would be required to determine if these factors are related, or if the decrease in interest paid is driven by factors such as debt reduction or refinancing at lower rates.

The observed trends suggest a strengthening financial position with respect to interest-bearing liabilities, or a change in capital structure. The fluctuating effective income tax rate warrants further scrutiny to understand its underlying drivers.


Enterprise Value to FCFF Ratio, Current

Vertex Pharmaceuticals Inc., current EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in thousands)
Enterprise value (EV)
Free cash flow to the firm (FCFF)
Valuation Ratio
EV/FCFF
Benchmarks
EV/FCFF, Competitors1
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences
EV/FCFF, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31).

1 Click competitor name to see calculations.

If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.


Enterprise Value to FCFF Ratio, Historical

Vertex Pharmaceuticals Inc., historical EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in thousands)
Enterprise value (EV)1
Free cash flow to the firm (FCFF)2
Valuation Ratio
EV/FCFF3
Benchmarks
EV/FCFF, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences
EV/FCFF, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 See details »

2 See details »

3 2025 Calculation
EV/FCFF = EV ÷ FCFF
= ÷ =

4 Click competitor name to see calculations.


The Enterprise Value to Free Cash Flow to the Firm (EV/FCFF) ratio exhibits considerable fluctuation over the observed period. Enterprise Value increased consistently from 2021 to 2024, while Free Cash Flow to the Firm (FCFF) demonstrated more volatility. Consequently, the EV/FCFF ratio shows a non-linear trend.

EV/FCFF Trend
In 2021, the EV/FCFF ratio stood at 22.47. A decrease was observed in 2022, with the ratio falling to 16.68. The ratio then increased significantly in 2023, reaching 29.45. A substantial shift occurred in 2024, with FCFF becoming negative, resulting in an undefined EV/FCFF ratio. The ratio rebounded in 2025 to 36.94, driven by a return to positive FCFF and continued growth in Enterprise Value.
Enterprise Value
Enterprise Value demonstrated a consistent upward trend throughout the period, increasing from US$55,209,611 thousand in 2021 to US$118,354,283 thousand in 2025. This indicates a growing overall valuation of the company, considering both equity and debt.
Free Cash Flow to the Firm
Free Cash Flow to the Firm experienced more variability. It increased from US$2,456,805 thousand in 2021 to US$3,966,256 thousand in 2022, before decreasing to US$3,372,501 thousand in 2023. A significant decline resulted in negative FCFF of US$-766,205 thousand in 2024, and then a recovery to US$3,204,352 thousand in 2025.

The fluctuation in the EV/FCFF ratio is largely attributable to the volatility in FCFF. The negative FCFF in 2024 is a notable outlier and warrants further investigation to understand the underlying causes. The increasing EV/FCFF ratio in 2025, despite positive FCFF, suggests that Enterprise Value is growing at a faster rate than Free Cash Flow to the Firm.